Search Results
Your search for it matches 15638 pages
Showing 12001 - 12050Phase II Trial Targeting Genetic Anomaly in Castration-resistant Metastatic Prostate Cancer Underway
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for castration-resistant metastatic prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout...
EGFR Prevents Maturation of microRNAs under Hypoxic Conditions
The epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs under conditions of hypoxia, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The results were reported in an early online...
Utilizing the Power of Rapid Learning Health-care Systems to Improve Patient Care
Lynn Etheredge’s career in shaping national health-care and social policy spans more than 4 decades and four Presidential administrations. He was the lead analyst in the development of health insurance proposals for Medicare and Medicaid while working in the White House Office of Management and...
Low-dose CT Detects Twice as Many Early-stage Lung Cancers as Chest X-ray, According to Additional NLST Results
Results of the first of three planned annual screening examinations from the National Lung Screening Trial (NLST) were recently published and physicians may now have more information to share with their patients about the benefits and risks of low-dose computed tomography lung cancer screening.1...
Peregrine Pharmaceuticals Reaches Agreement with FDA on Phase III Trial Design for Bavituximab in NSCLC
Peregrine Pharmaceuticals recently announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on a phase III registration trial design of the company’s lead clinical immunotherapeutic candidate bavituximab in second-line non–small cell lung cancer (NSCLC). The trial...
Evaluation of Lung Cancer Screening Strategy in the First Three Rounds of the NELSON Trial
The Dutch-Belgian Randomized Lung Cancer Screening Trial (Dutch acronym: NELSON study) was designed to investigate whether screening for lung cancer by low-dose multidetector computed tomography (CT) in high-risk subjects would lead to a decrease in 10-year lung cancer mortality of at least 25%...
Simultaneous EGFR Mutations and HER2 Gene Amplifications in Large Series of Patients with Non–Small Cell Lung Cancer
In a molecular profile analysis of 2,271 cases of non–small cell lung cancer (NSCLC), EGFR was mutated in 12% and KRAS in 32% of cases. HER2 gene amplification was confirmed as a rare event in NSCLC (4%). Coexistence of HER2 gene amplification and EGFR mutation was identified in three cases, while...
CancerProgress.Net Patient and Advocate Video Series Highlights Value and Impact of Cancer Research
“I’ve been living with melanoma for 7 years.” That’s a statement that, at the outset of her diagnosis, Joanne Maricle would have found surprising. Yet Joanne, who is featured in a video that is part of a new Patient and Advocate Video Series on ASCO’s CancerProgress.Net website, is able to lay...
Best of ASCO® Meetings Provide Intimate Access to Latest Research
Aiming to facilitate widespread dissemination of practice-changing research, ASCO offers the Best of ASCO® Meetings, which condense the most cutting-edge science and education from the ASCO Annual Meeting into a 2-day program. The smaller size of these meetings, compared to the Annual Meeting,...
Transforming Grand Rounds into Chartrounds: Technology and the Improving Cancer Care Grant Advance Patient Care
When Patricia Hardenbergh, MD, moved from her academic position as a breast radiation oncologist at Duke University to a small, rural practice in Edwards, Colorado, she realized that being a community oncologist was a very different experience. She was an expert in treating breast cancer and also...
Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
The Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group recently announced that it has appointed Joseph A. Sparano, MD, as its Vice Chair. In his new role, Dr. Sparano will assist the Group leadership in defining research...
Improving the Care and Study of Older Patients with Cancer
Predicting toxicity in older patients receiving chemotherapy is an important clinical problem. It has been shown that standard oncology measures such as performance status are not adequate to predict outcomes in the elderly. Clinical measures that are important in geriatric oncology are not...
Determining the Best Diet for Patients with Cancer
How much does diet and body weight influence the effectiveness of cancer treatment and reduce the risk of cancer recurrence? What is the optimal diet for patients with cancer and survivors to follow? There are currently no hard and fast rules, but some dietary clues are starting to emerge. Search...
A New Center for Lymphoid Malignancies Aims to Provide Precision Patient Care
In January, New York-Presbyterian Hospital/Columbia University Medical Center opened the Center for Lymphoid Malignancies, a 3,700 square foot outpatient clinic, in the heart of Midtown Manhattan. The Center is solely focused on the treatment of all forms of Hodgkin and non-Hodgkin lymphoma,...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood.1 Acute...
Cancer Organizations Recognize Sen. Shelby and Rep. DeLauro for Their Commitment to the Fight against Cancer
Sen. Richard Shelby (R-AL) and Rep. Rosa DeLauro (D-CT) were recognized recently by the American Society of Clinical Oncology, the American Association for Cancer Research, the Association of American Cancer Institutes, and Friends of Cancer Research for their outstanding commitment to cancer...
Double the Mastectomy, Double the Complications
A retrospective analysis of a large surgical database has documented that bilateral mastectomy is associated with a doubling in complication rates, compared with unilateral mastectomy. Researchers reported the findings at the 14th Annual Meeting of the American Society of Breast Surgeons in...
Expert Point of View: Alison Freifeld, MD
The EORTC Infectious Diseases Group Trial XV “is a long-awaited study because it finally is an investigation of outpatient management of low-risk fever and neutropenia in a large number of patients,” Alison Freifeld, MD, of the University of Nebraska Medical Center in Omaha, commented in an...
Once-daily Moxifloxacin for Low-risk Patients with Febrile Neutropenia
Once-daily oral moxifloxacin works at least as well as twice-daily oral ciprofloxacin plus amoxicillin–clavulanic acid when it comes to treating febrile neutropenia in patients who are at low risk for complications, according to a randomized, double-blind trial reported in the Journal of Clinical...
Death with Dignity Program at Seattle Cancer Care Alliance
After passage of the Washington Death with Dignity Act in November 2008, the Seattle Cancer Care Alliance—the site of outpatient care for patients with cancer from Fred Hutchinson–University of Washington Cancer Consortium—developed a Death with Dignity program. The program is adapted from existing ...
SIDEBAR: Physician-assisted Suicide
Readers’ comments extracted from www.nejm.org To force people to live simply because we possess the technology to do so does not speak to either the ethics or the morality of such a decision. Suffering has existential dimensions. Symptoms can be treated with greatest chance. My grandfather...
Expert Point of View: Andrew D. Zelenetz, MD, PhD
In a separate interview, Andrew D. Zelenetz, MD, PhD, Chief of the Lymphoma Service at Memorial Sloan-Kettering Cancer Center in New York, said that he found the relapse rate of 20% observed in this study to be quite low, and he wanted to know the characteristics of the 537 patients included in the ...
Potent Activity Shown for First-in-class PI3K-delta Inhibitor in Chronic Lymphocytic Leukemia
Heavily pretreated patients with chronic lymphocytic leukemia (CLL) responded robustly to the first-in-class small-molecule inhibitor idelalisib (formerly GS1101), in a phase I dose-finding study reported in a press briefing prior to the 2013 ASCO Annual Meeting.1 Idelalisib, a specific inhibitor...
Expert Point of View: Roy S. Herbst, MD, PhD
This study should be placed in the context of treating to cure, said Roy S. Herbst, MD, PhD, Ensign Professor of Medicine and Chief of Medical Oncology at Yale University School of Medicine, New Haven, Connecticut. “If we can further increase the cure rate in stage III non–small cell lung cancer...
Impressive Results Shown for Immune Checkpoint Inhibitors: Anti-PD1 and Anti-PD-L1 Antibodies
Antibody-mediated blockade of the programmed death 1 protein (PD-1) and its ligand (PD-L1) resulted in potent and durable tumor regression and prolonged stabilization of disease in patients with advanced solid tumors, according to early data on these drugs presented at the 2013 ASCO Annual Meeting. ...
'Less Is More' with Regard to Adjuvant Radiation in Stage III Non–Small Cell Lung Cancer
Standard-dose conformal radiotherapy (60 Gy) is more effective and safer than high-dose radiotherapy (74 Gy) in patients with locally advanced stage III non–small cell lung cancer (NSCLC) undergoing chemotherapy, according to results of the phase III randomized, controlled Radiation Therapy...
One Cancer Center's Approach to Death with Dignity
In November 2008, the Washington State legislature passed the Washington Death with Dignity Act allowing patients with a terminal diagnosis and less than 6 months to live to request and self-administer lethal medication. After considerable internal debate, our cancer center elected to develop a...
Caring for the Whole Patient Both during Active Treatment and at End of Life
Despite studies showing that a majority of patients prefer to die at home rather than in an institutional setting,1 in many parts of the country, over 30% die in nursing homes and over 50% die in hospitals, according to Ira Byock, MD, Director of Palliative Medicine, Dartmouth-Hitchcock Medical...
SIDEBAR: Understanding the PD-1/PD-L1 Pathway and Its Promise
Tumors can be recognized by the immune system, but they have multiple mechanisms for evading eradication by the immune system. The tumor microenvironment suppresses the immune response, partly because tumors can express molecules that inhibit immune responses. The cancer clinical trials summarized...
For Renowned Researcher, Seeing Basic Science Turn into Promising Therapies Is the 'Holy Grail' of Oncology
“From bench to bedside” is a phrase that captures the essence of modern oncology: Researchers at the bench seek to solve the biologic puzzles of cancer that can translate into the development of therapeutics delivered at the bedside. Owen N. Witte, MD, has spent most of his career as a basic bench...
Innovative Leader in Oncology Is Committed to Tackling the Most Critical Issues in Managed Care
“I’m a Nebraskan,” said Lee N. Newcomer, MD, MHA, a leader in the oncology community who is well known for his innovative efforts to align physician payment and quality of care in ways that will best configure to the rapidly changing health-care environment. Speaking in the flat vowels and neutral...
The Power of Listening: From Candy Striper to the Front Lines of the Early AIDS Pandemic
Alexandra Levine, MD, MACP, the Chief Medical Officer of City of Hope National Medical Center, has traveled to 74 countries, seeking out adventures in some of the world’s most far-flung regions. Her illustrious oncology journey has also been an adventure, from the front lines of the AIDS pandemic...
Expert Genitourinary Oncologist's Drive Led Her from Baghdad to the United States
Born in Baghdad, Iraq, renowned prostate and bladder cancer specialist Maha H. Hussain, MD, FACP, Professor of Medicine and Urology at the University of Michigan Comprehensive Cancer Center, remembers that she always wanted to become a doctor. She had strong role models in three uncles who were...
UICC President Balances Innovation and Pragmatism to Reduce the Global Burden of Cancer
Mary K. Gospodarowicz, MD, FRCPC, is determined to help reduce the worldwide burden of cancer, a problem of epic proportions. Her approach is simple: adopt what works and reject what doesn’t. Much progress in the fight against cancer can be made without waiting for the next paradigm-changing...
Pioneering Oncologist's Research on Cisplatin Revolutionized Testicular Cancer Treatment
Lawrence H. Einhorn, MD, grew up in Dayton, Ohio, in a time and place that he describes as pleasant and community-oriented. Throughout his distinguished career, Dr. Einhorn has maintained strong roots in the Midwest. “After finishing high school, I did my undergrad at Indiana University and went to ...
After a Distinguished Career, Trailblazing Swiss Oncologist Remains Devoted to Addressing the Global Cancer Challenge
Switzerland, a landlocked country with a population about that of New York City, has four geographic regions, each with its own official language. Internationally regarded lymphoma and breast cancer expert, Franco Cavalli, MD, FRCP, was born and raised in Locarno, a town in the Italian region of...
Distinguished Researcher Changed the Face of Hematologic Malignancies
Clara D. Bloomfield, MD, grew up in a steadfastly academic environment that spurned typical children’s entertainment such as comic books or television. Born in New York City during World War II, she moved to Washington, DC, with her family while her father, an expert on labor and industrial...
Prolific Surgical Oncologist Understands the True Value of Mentorship
Charles M. Balch, MD, FACS, PhD (hc), was born in Milford, Delaware, where his father was a research chemist for DuPont during World War II. “My father was part of the team that developed rayon for parachutes. It was a top priority program because they couldn’t get nylon from the Philippines. After ...
The Road to ASCO Presidency, Paved by Education and Persistence
ASCO President Clifford A. Hudis, MD, grew up in northeast Philadelphia in the 1960s, a robust period in U.S. history dominated by American industry and ingenuity. His early memories are of a hard-working blue-collar neighborhood of identical row and semidetached twin houses and of a time of...
Emil 'Tom' Frei III, MD 1924–2013
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
'Matriarch of Modern Cancer Genetics,' Janet D. Rowley, MD, Helped Propel the Field of Molecular Oncology
Even as a child, Janet D. Rowley, MD, found the intellectual order and logic of science appealing. Born on April 5, 1925, in New York, Dr. Rowley’s parents, Hurford and Ethel Ballantyne Davison, moved the family to Chicago 2 years later. Both educators, the Davisons encouraged their only child in...
DCIS Score Quantifies Risk of Recurrence after Excision
The ductal carcinoma in situ (DCIS) Score, a multigene expression assay, quantifies the risk of local recurrence and invasive local recurrence for women with DCIS treated with surgical excision, researchers reported in the Journal of the National Cancer Institute. “The DCIS Score can aid clinical...
Chemotherapy-induced Peripheral Neuropathy Results in Dose Limiting and Less Chemotherapy Overall
Chemotherapy-induced peripheral neuropathy events resulted in limiting the dosing of chemotherapy in a significant proportion of women with nonmetastatic breast cancer being treated with paclitaxel, and those who had their dose reduced or discontinued received significantly less cumulative drug,...
Angelina Jolie's Disclosure of Prophylactic Bilateral Mastectomy: A Positive Example for Women with BRCA Mutations?
Angelina Jolie, in a New York Times article entitled “My Medical Choice,”1 disclosed that having a BRCA1 mutation and an estimated 87% risk of breast cancer, “I decided to be proactive and minimize the risk as much I could. I made a decision to have a preventive double mastectomy.” She was writing...
Living Without Fear
Even before I had a colonoscopy to determine the cause of abdominal pains I had been having, I instinctively knew that the news wouldn’t be good. A colonoscopy and subsequent pathology report confirmed stage IIIC colorectal cancer. Because I was just 47 years old at the time of my diagnosis and had ...
Focus on the Georgia Society of Clinical Oncology
With a roster of over 600 members that includes community and institutional oncologists, administrators, registered nurses, and patient navigators, the Georgia Society of Clinical Oncology (GASCO) is one of ASCO’s largest State Affiliates. Founded in 1986, the Atlanta-based Society is active in...
Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was approved by...
Partnership Seeks to Accelerate Development of Innovative Therapies
The Leukemia & Lymphoma Society (LLS) recently joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This Blood Cancer Research Partnership (BCRP) will...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center...
How to Recognize and Manage Hand-Foot Syndrome Due to Capecitabine or Doxorubicin
Dermatologic Events in Oncology is guest edited by Mario E. Lacouture, MD, an Associate Member in the Division of Dermatology, Department of Medicine, at Memorial Sloan-Kettering Cancer Center, New York. He is a board-certified dermatologist with a special interest in dermatologic conditions that...
